Replies to post #333583 on Anavex Life Sciences Corp (AVXL)

[GD]

AVXL only needs to report the topline on primary efficacy endpoints data,
P value which street cares the most, the trial either passes or fails the test
only, rest of detail analysis is just data mining to understand what is
going on. To your credit, Missling keeps talking dig deep into biomarkers
is not giving street comfort of approval based on PII results, IMO.
And why not to do "PDD style chop in two stunt" like last year if
the data is strong positive, it will leak out if having results in
hand and holding too long. PDD-001 trial ended in Sept, topline on OCT 14,
presentation on Nov 6 is right way to inform us all, IMO.